Literature DB >> 16685110

Functional variation in VEGF is not associated with type 2 diabetes in a United Kingdom Caucasian population.

Rachel M Freathy1, Michael N Weedon, Beverley Shields, Graham A Hitman, Mark Walker, Mark I McCarthy, Andrew T Hattersley, Timothy M Frayling.   

Abstract

CONTEXT: Vascular endothelial growth factor (VEGF) is important for pancreatic beta cell development and function. Common variation in the VEGF gene is associated with altered serum concentrations of VEGF and with several diseases, but its role in type 2 diabetes is not known. The single nucleotide polymorphisms C-2578A (rs699947), G-1154A (rs1570360) and G-634C (rs2010963) in the 5'-region of VEGF are associated with altered serum concentrations of the protein.
OBJECTIVE: We performed a large case-control and family-based study to test the hypothesis that these variants are associated with type 2 diabetes in a UK Caucasian population. PARTICIPANTS: We genotyped 1,969 cases, 1,625 controls and 530 families for the three single nucleotide polymorphisms. MAIN OUTCOME MEASURES: Allele and genotype frequencies were compared between cases and controls. Family-based analysis was used to test for over- or under-transmission of alleles to affected offspring.
RESULTS: Despite good power (80%) to detect odds ratios of approximately 1.2, there were no significant associations between single alleles or genotypes and type 2 diabetes. Odds ratios (and 95% confidence intervals) comparing case and control allele frequencies for single nucleotide polymorphisms C-2578A, G-1154A and G-634C were 0.97 (0.88-1.07), 0.99 (0.90-1.09) and 0.97 (0.88-1.08), respectively.
CONCLUSION: This is the first large-scale study to examine the association between common functional variation in VEGF and type 2 diabetes risk. We have found no evidence that these three single nucleotide polymorphisms, shown previously to alter VEGF concentrations, are risk factors for type 2 diabetes in a large UK Caucasian case-control and family-based study.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16685110

Source DB:  PubMed          Journal:  JOP        ISSN: 1590-8577


  4 in total

1.  Evaluation of VEGF gene polymorphisms and proliferative diabetic retinopathy in Mexican population.

Authors:  Roberto Gonzalez-Salinas; Maria C Garcia-Gutierrez; Gerardo Garcia-Aguirre; Virgilio Morales-Canton; Raul Velez-Montoya; Vidal R Soberon-Ventura; Victoria Gonzalez; Rodrigo Lechuga; Pablo Garcia-Solis; David G Garcia-Gutierrez; Marco Vinicio Garcia-Solis; Manuel Saenz de Viteri; Juan C Solis-S
Journal:  Int J Ophthalmol       Date:  2017-01-18       Impact factor: 1.779

2.  Variants of SLC2A10 may be Linked to Poor Response to Metformin.

Authors:  Elizabeth Paz-Pacheco; Jose B Nevado; Eva Maria C Cutiongco-de la Paz; Gabriel V Jasul; Aimee Yvonne Criselle L Aman; Elizabeth Laurize A Ribaya; Mark David G Francisco; Ma Luz Vicenta V Guanzon; May L Uyking-Naranjo; Ma Cecille S Añonuevo-Cruz; Maria Patricia Deanna D Maningat; Cristina V Jaring; Paulette D Nacpil-Dominguez; Aniza B Pala-Mohamad; Abigail U Canto; John Paul M Quisumbing; Annabelle Marie M Lat; Diane Carla C Bernardo; Noemie Marie M Mansibang; Karell Jo Angelique C Calpito; Vincent Sean D Ribaya; Julius Patrick Y Ferrer; Jessica H Biwang; Jodelyn B Melegrito; Christian Deo T Deguit; Carlos Emmanuel G Panerio
Journal:  J Endocr Soc       Date:  2022-06-29

3.  Vascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia.

Authors:  Carol Lozano-Santos; Jimena Martinez-Velasquez; Belen Fernandez-Cuevas; Natividad Polo; Belen Navarro; Isabel Millan; Jose Miguel Garcia; Rosa Collado; Pedro Sanchez-Godoy; Felix Carbonell; Jose Antonio Garcia-Vela; Jose Antonio Garcia-Marco; Natalia Gomez-Lozano
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240

4.  Association of common polymorphisms in the VEGFA and SIRT1 genes with type 2 diabetes-related traits in Mexicans.

Authors:  Armando Totomoch-Serra; Maria de Lourdes Muñoz; Juan Burgueño; Maria Cristina Revilla-Monsalve; Alvaro Diaz-Badillo
Journal:  Arch Med Sci       Date:  2018-03-28       Impact factor: 3.318

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.